Update on antifungal agents for paediatric patients

Clinical Microbiology and Infection

Volumn 16, Issue 9, 2010, Pages 1343-1353

  Groll, A H ^a   Tragiannidis, A ^b  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

5 Fluorocytosine; Amphotericin B deoxycholate; Anidulafungin; Caspofungin; Fluconazole; Intraconazole; Lipid formulations of amphotericin B; Micafungin; Posaconazole; Review; Voriconazole

Indexed keywords

AMPHOTE; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; CREATININE; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; UNCLASSIFIED DRUG; VORICONAZOLE;

ABNORMAL VISION; APPLICATION SITE PHOTOSENSITIVITY REACTION; AREA UNDER THE CURVE; ASPERGILLOSIS; BONE MARROW TOXICITY; CANDIDA MENINGITIS; CANDIDIASIS; CHILL; CHROMOMYCOSIS; CLINICAL TRIAL; COCCIDIOIDOMYCOSIS; CREATININE BLOOD LEVEL; CRYPTOCOCCAL MENINGITIS; DISTRIBUTION VOLUME; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FEVER; DRUG FORMULATION; DRUG HALF LIFE; DRUG MONITORING; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FUSARIOSIS; GASTROINTESTINAL SYMPTOM; GRANULOCYTOPENIA; HUMAN; IMMUNE DEFICIENCY; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; LIVER DISEASE; LIVER FUNCTION TEST; LIVER TOXICITY; LIVER TUMOR; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MYCOSIS; NEPHROTOXICITY; NONHUMAN; OROPHARYNX CANDIDIASIS; PEDIATRICS; PHOTOTOXICITY; PRIORITY JOURNAL; PSEUDALLESCHERIASIS; RECOMMENDED DRUG DOSE; REVIEW; RIGOR; SIDE EFFECT; SKIN DISEASE; SKIN EXFOLIATION; SQUAMOUS CELL CARCINOMA; VISUAL FIELD DEFECT; VOMITING; ZYGOMYCOSIS;

EID: 77956130615     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2010.03334.x     Document Type: Review

References (85)

1. Nath CE, Shaw PJ, Gunning R, McLachlan AJ, Earl JW. Amphotericin B in children with malignant disease: a comparison of the toxicities and pharmacokinetics of amphotericin B administered in dextrose versus lipid emulsion. Antimicrob Agents Chemother 1999, 43:1417-1423.
2. Nath CE, McLachlan AJ, Shaw PJ, Gunning R, Earl JW. Population pharmacokinetics of amphotericin B in children with malignant diseases. Br J Clin Pharmacol 2001, 52:671-680.
3. Kingo AR, Smyth JA, Waisma D. Lack of evidence of amphotericin B toxicity in very low birth weight infants treated for systemic candidiasis. Pediatr Infect Dis J 1997, 16:1002-1003.
4. Prentice HG, Hann IM, Herbrecht R. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997, 98:711-718.
5. Le J, Adler-Shohet FC, Nguyen C, Lieberman JM. Nephrotoxicity associated with amphotericin B deoxycholate in neonates. Pediatr Infect Dis J 2009, 28:1061-1063.
6. Butler KM, Rench MA, Baker CJ. Amphotericin B as a single agent in the treatment of systemic candidiasis in neonates. Pediatr Infect Dis J 1990, 9:51-56.
7. Leibovitz E, Iuster-Reicher A, Amitai M, Mogilner B. Systemic candidal infections associated with use of peripheral venous catheters in neonates: a 9-year experience. Clin Infect Dis 1992, 14:485-491.
8. Glick C, Graves GR, Feldman S. Neonatal fungemia and amphotericin B. South Med J 1993, 86:1368-1371.
9. Groll AH, Muller FM, Piscitelli SC, Walsh TJ. Lipid formulations of amphotericin B: clinical perspectives for the management of invasive fungal infections in children with cancer. Klin Padiatr 1998, 210:264-273.
10. Amantea MA, Bowden RA, Forrest A, Working PK, Newman MS, Mamelok RD. Population pharmacokinetics and renal function-sparing effects of amphotericin B colloidal dispersion in patients receiving bone marrow transplants. Antimicrob Agents Chemother 1995, 39:2042-2047.
11. Sandler ES, Mustafa MM, Tkaczewski I. Use of amphotericin B colloidal dispersion in children. J Pediatr Hematol Oncol 2000, 22:242-246.
12. Walsh TJ, Whitcomb P, Piscitelli S. Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis. Antimicrob Agents Chemother 1997, 41:1944-1948.
13. Walsh TJ, Seibel NL, Arndt C. Amphotericin B lipid complex in pediatric patients with invasive fungal infections. Pediatr Infect Dis J 1999, 18:702-708.
14. Wiley JM, Seibel NL, Walsh TJ. Efficacy and safety of amphotericin B lipid complex in 548 children and adolescents with invasive fungal infections. Pediatr Infect Dis J 2005, 24:167-174.
15. Wurthwein G, Groll AH, Hempel G, Adler-Shohet FC, Lieberman JM, Walsh TJ. Population pharmacokinetics of amphotericin B lipid complex in neonates. Antimicrob Agents Chemother 2005, 49:5092-5098.
16. Hong Y, Shaw PJ, Nath CE. Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases. Antimicrob Agents Chemother 2006, 50:935-942.
17. Queiroz-Telles F, Berezin E, Leverger G. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr Infect Dis J 2008, 27:820-826.
18. Maertens JA, Madero L, Reilly AF. A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia. Pediatr Infect Dis J 2010, 29:415-420.
19. Kolve H, Ahlke E, Fegeler W, Ritter J, Jürgens H, Groll AH. Safety, tolerance and outcome of treatment with liposomal amphotericin B in paediatric patients with cancer or undergoing haematopoietic stem cell transplantation. J Antimicrob Chemother 2009, 64:383-387.
20. Juster-Reicher A, Leibovitz E, Linder N. Liposomal amphotericin B (AmBisome) in the treatment of neonatal candidiasis in very low birth weight infants. Infection 2000, 28:223-226.
21. Juster-Reicher A, Flidel-Rimon O, Amitay M, Even-Tov S, Shinwell E, Leibovitz E. High-dose liposomal amphotericin B in the therapy of systemic candidiasis in neonates. Eur J Clin Microbiol Infect Dis 2003, 22:603-607.
22. Groll AH, Ritter J. Diagnosis and management of fungal infections and pneumocystis pneumonitis in pediatric cancer patients. Klin Padiatr 2005, 217(suppl 1):S37-S66.
23. Cornely OA, Maertens J, Bresnik M. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007, 44:1289-1297.
24. Kuse ER, Chetchotisakd P, da Cunha CA. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007, 369:1519-1527.
25. Groll AH, Piscitelli SC, Walsh TJ. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol 1998, 44:343-500.
26. Bennett JE, Dismukes WE, Duma RJ. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N Engl J Med 1979, 301:126-131.
27. van der Horst CM, Saag MS, Cloud GA. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 1997, 337:15-21.
28. Smego RA, Perfect JR, Durack DT. Combined therapy with amphotericin B and 5-fluorocytosine for Candida meningitis. Rev Infect Dis 1984, 6:791-801.
29. Fernandez M, Moylett EH, Noyola DE, Baker CJ. Candidal meningitis in neonates: a 10-year review. Clin Infect Dis 2000, 31:458-463.
30. McCullers JA, Vargas SL, Flynn PM, Razzouk BI, Shenep JL. Candidal meningitis in children with cancer. Clin Infect Dis 2000, 31:451-457.
31. Benjamin DK, Stoll BJ, Fanaroff AA. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics 2006, 117:84-92.
32. Baley JE, Meyers C, Kliegman RM, Jacobs MR, Blumer JL. Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates. J Pediatr 1990, 116:791-797.
33. Soltani M, Tobin CM, Bowker KE, Sunderland J, MacGowan AP, Lovering AM. Evidence of excessive concentrations of 5-flucytosine in children aged below 12 years: a 12-year review of serum concentrations from a UK clinical assay reference laboratory. Int J Antimicrob Agents 2006, 28:574-577.
34. Hope WW, Warn PA, Sharp A. Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: a pharmacodynamic rationale for reduced dosing. Antimicrob Agents Chemother 2007, 51:3760-3762.
35. Francis P, Walsh TJ. Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy. Clin Infect Dis 1992, 15:1003-1018.
36. Lee JW, Seibel NL, Amantea M, Whitcomb P, Pizzo PA, Walsh TJ. Safety and pharmacokinetics of fluconazole in children with neoplastic diseases. J Pediatr 1992, 120:987-993.
37. Brammer KW, Coates PE. Pharmacokinetics of fluconazole in pediatric patients. Eur J Clin Microbiol Infect Dis 1994, 13:325-329.
38. Saxen H, Hoppu K, Pohjavuori M. Pharmacokinetics of fluconazole in very low birth weight infants during the first two weeks of life. Clin Pharmacol Ther 1993, 54:269-277.
39. Wade KC, Wu D, Kaufman DA. Population pharmacokinetics of fluconazole in young infants. Antimicrob Agents Chemother 2008, 52:4043-4049.
40. Novelli V, Holzel H. Safety and tolerability of fluconazole in children. Antimicrob Agents Chemother 1999, 43:1955-1960.
41. Pappas PG, Rex JH, Sobel JD. Guidelines for treatment of candidiasis. Clin Infect Dis 2004, 38:161-189.
42. Fasano C, O'Keeffe J, Gibbs D. Fluconazole treatment of neonates and infants with severe fungal infections not treatable with conventional agents. Eur J Clin Microbiol Infect Dis 1994, 13:351-354.
43. Bilgen H, Ozek E, Korten V, Ener B, Molbay D. Treatment of systemic neonatal candidiasis with fluconazole. Infection 1995, 23:394.
44. Driessen M, Ellis JB, Muwazi F, De Villiers FP. The treatment of systemic candidiasis in neonates with oral fluconazole. Ann Trop Paediatr 1997, 17:263-271.
45. Driessen M, Ellis JB, Cooper PA. Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: a prospective randomized trial. Pediatr Infect Dis J 1996, 15:1107-1112.
46. Wainer S, Cooper PA, Gouws H, Akierman A. Prospective study of fluconazole therapy in systemic neonatal fungal infection. Pediatr Infect Dis J 1997, 16:763-767.
47. Huttova M, Hartmanova I, Kralinsky K. Candida fungemia in neonates treated with fluconazole: report of forty cases, including eight with meningitis. Pediatr Infect Dis J 1998, 17:1012-1015.
48. Wade KC, Benjamin DK, Kaufman DA. Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants. Pediatr Infect Dis J 2009, 28:717-723.
49. Kaufman D, Boyle R, Hazen KC, Patrie JT, Robinson M, Donowitz LG. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med 2001, 345:1660-1666.
50. Manzoni P, Stolfi I, Pugni L. A multicenter, randomized trial of prophylactic fluconazole in preterm neonates. N Engl J Med 2007, 356:2483-2495.
51. de Repentigny L, Ratelle J, Leclerc JM. Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children. Antimicrob Agents Chemother 1998, 42:404-408.
52. Groll AH, Wood L, Roden M. Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis. Antimicrob Agents Chemother 2002, 46:2554-2463.
53. Hennig S, Wainwright CE, Bell SC, Miller H, Friberg LE, Charles BG. Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients. Clin Pharmacokinet 2006, 45:1099-1114.
54. Abdel-Rahman SM, Jacobs RF, Massarella J. Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents. Antimicrob Agents Chemother 2007, 51:2668-2673.
55. Foot AB, Veys PA, Gibson BE. Itraconazole oral solution as antifungal prophylaxis in children undergoing stem cell transplantation or intensive chemotherapy for haematological disorders. Bone Marrow Transplant 1999, 24:1089-1093.
56. Caillot D, Bassaris H, McGeer A. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin Infect Dis 2001, 33:e83-e90.
57. Walsh TJ, Karlsson MO, Driscoll T. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother 2004, 48:2166-2172.
58. Yanni SB, Annaert PP, Augustijns P, Ibrahim JG, Benjamin DK, Thakker DR. In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3. Drug Metab Dispos 2010, 38:25-31.
59. Karlsson MO, Lutsar I, Milligan PA. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob Agents Chemother 2009, 53:935-944.
60. Neely M, Rushing T, Kovacs A, Jelliffe R, Hoffman J. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin Infect Dis 2010, 50:27-36.
61. Shima H, Miharu M, Osumi T, Takahashi T, Shimada H. Differences in voriconazole trough plasma concentrations per oral dosages between children younger and older than 3 years of age. Pediatr Blood Cancer 2010, 54:1050-1052.
62. Walsh TJ, Lutsar I, Driscoll T. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002, 21:240-248.
63. Kolve HLT, Ehlert K, Paulussen M. Safety, tolerance and plasma concentrations of voriconazole in immunocompromised pediatric patients. Clin Microbiol Infect 2004, 10:40-41.
64. Cowen EW, Nguyen JC, Miller DD. Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. J Am Acad Dermatol 2010, 62:31-37.
65. Groll AH, Walsh TJ. Posaconazole: clinical pharmacology and potential for management of fungal infections. Expert Rev Anti Infect Ther 2005, 3:467-487.
66. Krishna G, Sansone-Parsons A, Martinho M, Kantesaria B, Pedicone L. Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. Antimicrob Agents Chemother 2007, 51:812-818.
67. Lehrnbecher T, Attarbaschi A, Duerken M. Posaconazole salvage treatment in paediatric patients: a multicentre survey. Eur J Clin Microbiol Infect Dis 2010, 29:1043-1045.
68. Benjamin DK, Driscoll T, Seibel NL. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother 2006, 50:632-638.
69. Groll AH, Walsh TJ. Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections. Expert Opin Investig Drugs 2001, 10:1545-1558.
70. Walsh TJ, Adamson PC, Seibel NL. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother 2005, 49:4536-4545.
71. Neely M, Jafri HS, Seibel N. Pharmacokinetics and safety of caspofungin in older infants and toddlers. Antimicrob Agents Chemother 2009, 53:1450-1456.
72. Sáez-Llorens X, Macias M, Maiya P. Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age. Antimicrob Agents Chemother 2009, 53:869-875.
73. Zaoutis T, Lehrnbecher T, Groll AH. Safety experience with caspofungin in pediatric patients. Pediatr Infect Dis J 2009, 28:1132-1135.
74. Franklin JA, McCormick J, Flynn PM. Retrospective study of the safety of caspofungin in immunocompromised pediatric patients. Pediatr Infect Dis J 2003, 22:747-749.
75. Groll AH, Attarbaschi A, Schuster FR. Treatment with caspofungin in immunocompromised paediatric patients: a multicentre survey. J Antimicrob Chemother 2006, 57:527-535.
76. Natarajan G, Lulic-Botica M, Rongkavilit C, Pappas A, Bedard M. Experience with caspofungin in the treatment of persistent fungemia in neonates. J Perinatol 2005, 25:770-777.
77. Odio CM, Araya R, Pinto LE. Caspofungin therapy of neonates with invasive candidiasis. Pediatr Infect Dis J 2004, 23:1093-1097.
78. Seibel NL, Schwartz C, Arrieta A. Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother 2005, 49:3317-3324.
79. Hope WW, Seibel NL, Schwartz CL. Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. Antimicrob Agents Chemother 2007, 51:3714-3719.
80. Heresi GP, Gerstmann DR, Reed MD. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J 2006, 25:1110-1115.
81. Hope WW, Mickiene D, Petraitis V. The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. J Infect Dis 2008, 197:163-171.
82. Smith PB, Walsh TJ, Hope W. Pharmacokinetics of an elevated dosage of micafungin in premature neonates. Pediatr Infect Dis J 2009, 28:412-415.
83. Hope WW, Smith PB, Arrieta A. Population pharmacokinetics of micafungin in neonates and young infants. Antimicrob Agents Chemother 2010, 54:2633-2637.
84. Benjamin DK, Smith PB, Arrieta A. Safety and pharmacokinetics of repeat-dose micafungin in young infants. Clin Pharmacol Ther 2010, 87:93-99.
85. Dornbusch HJ, Manzoni P, Roilides E, Walsh TJ, Groll AH. Invasive fungal infections in children. Pediatr Infect Dis J 2009, 28:734-737.